We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Covis Group S.à r.l. today announced that data demonstrating that the investigational anticoagulant reversal agent ciraparantag binds to unfractionated heparin, low molecular weight heparin (LMWH) and direct oral anticoagulants (DOACs) were published ...
Covis Group S.à r.l. announced the completion of its acquisition of AMAG Pharmaceuticals, Inc. through the successful tender offer for all of the outstanding shares of common stock of AMAG at $13.75 per share in cash and subsequent merger.